Single-cell RNA sequencing of CT26 murine tumors: treated versus untreated comparison
This study utilizes single-cell RNA sequencing (scRNA-seq) to characterize the cellular heterogeneity of the tumor microenvironment in a murine CT26 colon carcinoma model. The primary objective is to compare the transcriptomic profiles of tumor cells and infiltrating immune cells between drug-treated and untreated CT26 tumors. CT26 tumor cells were subcutaneously implanted into BALB/c mice. Following tumor establishment, animals were randomized into treatment and control groups. Tumors were harvested, dissociated into single-cell suspensions, and processed for scRNA-seq using the 10x Chromium platform. Sequencing was performed on an Illumina NovaSeq 6000 platform.The resulting dataset enables comprehensive profiling of treatment-induced transcriptional changes across diverse cell populations within the tumor microenvironment, including malignant cells, T lymphocytes, myeloid cells, and other stromal components. By comparing treated versus untreated conditions, this study aims to identify differentially expressed genes and pathways associated with therapeutic response, as well as to characterize treatment-associated shifts in immune cell composition and functional states. This resource provides a valuable foundation for understanding the cellular and molecular mechanisms underlying drug efficacy and resistance in the CT26 model, and may inform the development of combination immunotherapies.